JLHL

Jupiter Life Line Hospitals share price & financials

Price
₹1,553
Market cap
₹9.2k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 03 Aug 2026

Jupiter Life Line Hospitals Limited Q1 FY27

EBITDA ₹79.3 cr EBITDA Margin 19.3% PAT ₹37.5 cr Total Income ₹411 cr

What went well

  • Total income for Q1 FY27 reached INR411 crores.
  • PAT for the quarter was INR37.5 crores.
  • ARPOB for the quarter stood at INR73,500, indicating strong revenue per bed.

What to watch

  • Dombivli Hospital contributed an INR9.5 crores drag on EBITDA in its first full quarter of operations.
  • Indore unit's EBITDA margins came in lower at 12% due to higher costs from new team buildup and doctor hires.
Read the full call →

What Jupiter Life Line Hospitals Limited does

Jupiter Life Line Hospitals operates multi-specialty tertiary and quaternary care hospitals in Western India, earning revenue from inpatient (IPD) and outpatient (OPD) medical services including cardiology, oncology, orthopaedics, nephrology, neurology, organ transplant and other specialities. Each hospital follows an 'all-hub-no-spoke' model, functioning as a fully equipped, independent centre capable of delivering comprehensive care rather than relying on smaller feeder facilities. The Thane hospital additionally houses a multi-organ transplant centre. The company is expanding via both greenfield hospital construction and brownfield capacity additions at existing sites.

Segments

  • IPD (Inpatient)
  • OPD (Outpatient)
Operating hospitals
4 hospitals — Thane, Pune (Baner), Indore and Dombivli (MMR)
Operational bed capacity
1,248 beds (FY26)
Doctors
1,275
Specialities/departments offered
30+
Hospitals under construction/development
3 greenfield projects — Pune-Bibwewadi, Mira-Bhayandar and BKC (Mumbai)
Operating model
All-Hub-No-Spoke — each hospital is a fully equipped, independent tertiary/quaternary care centre
Company website

Guidance record · Q1 FY27

what the last two calls moved 15 tracked 2 delivered 1 missed 12 open
  • ARPOB Growth (Thane/Pune) delivered said Q4 FY25 Promised: inflation-linked Q1 FY27: Q1 ARPOB stood at INR 73,500, representing a ~10% growth, driven by case mix, contract renegotiations, and pricing. Continues to exceed inflation.
  • Dombivli Hospital Operational Date delivered said Q3 FY25 Promised: Q1 FY26-27 Q1 FY27: Not mentioned; promise already achieved.
  • Debt for New Hospitals diluted said Q3 FY25 Promised: will not need more debt. Internal accruals and cash reserves will be sufficient Q1 FY27: Maintains net debt of zero but with INR 500 cr gross debt. Future funding from internal accruals, with potential debt only towards end of expansion cycle, within 3x EBITDA ceiling.

All 15 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 16.4%, net profit down 13.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue335 333 337 353 394 +18%365 +10%388 +15%411 +16%
EBITDA78 76 80 78 92 +18%83 +9%89 +11%79 +1%
Net profit52 52 45 44 57 +10%42 −19%50 +11%38 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −81.1% 1Y

₹0.5k₹1.0k₹1.5kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 2 Feb 2026Q4 FY26 — 18 May 2026Q1 FY27 — 3 Aug 2026

1Y: ₹1,477.3 on 10 Sept 2025 → ₹279.15. High ₹1,595.2 (30 Oct 2025), low ₹279.15 (11 Sept 2026).

How the price took the results

close before → close after

Q1 FY27
−3.8%
3 Aug
Q4 FY26
+0.9%
18 May
Q3 FY26
−4.5%
2 Feb
Q2 FY26
−2.5%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 18.9% a year over 3 years, FY23 to FY26. Operating margin held at 22.8%.

Year endingFY23FY24FY25FY26
Revenue₹892 Cr₹1.1k Cr₹1.3k Cr₹1.5k Cr
Operating profit₹201 Cr₹239 Cr₹299 Cr₹342 Cr
Operating margin22.5%22.3%23.1%22.8%
Interest₹42 Cr₹26 Cr₹11 Cr₹33 Cr
Depreciation₹39 Cr₹43 Cr₹57 Cr₹87 Cr
Net profit₹73 Cr₹177 Cr₹194 Cr₹193 Cr
Net margin8.2%16.5%15.0%12.9%
Cash from operations₹176 Cr₹115 Cr₹267 Cr₹268 Cr
Free cash flow₹100 Cr₹29 Cr₹-60 Cr₹-234 Cr
ROCE21.0%22.0%18.0%15.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹51 Cr₹51 Cr₹57 Cr₹66 Cr₹66 Cr₹66 Cr
Reserves₹188 Cr₹243 Cr₹309 Cr₹1.1k Cr₹1.4k Cr₹1.5k Cr
Borrowings₹426 Cr₹495 Cr₹469 Cr₹0 Cr₹403 Cr₹584 Cr
Other liabilities₹124 Cr₹120 Cr₹151 Cr₹112 Cr₹168 Cr₹235 Cr
Total liabilities₹789 Cr₹909 Cr₹986 Cr₹1.3k Cr₹2.0k Cr₹2.4k Cr
Fixed assets₹630 Cr₹684 Cr₹720 Cr₹718 Cr₹998 Cr₹1.4k Cr
Capital work in progress₹26 Cr₹27 Cr₹29 Cr₹74 Cr₹296 Cr₹129 Cr
Investments₹7 Cr₹3 Cr₹2 Cr₹17 Cr₹526 Cr₹486 Cr
Other assets₹126 Cr₹195 Cr₹235 Cr₹473 Cr₹203 Cr₹364 Cr
Total assets₹789 Cr₹909 Cr₹986 Cr₹1.3k Cr₹2.0k Cr₹2.4k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs added +0.69 pp while FIIs trimmed −0.40 pp. The shareholder count shrank 3% to 33,194.

Promoters
40.9%
FIIs
9.4%
DIIs
16.5%
Public
33.2%

Since Jun 2025

  • DIIs +0.69 pp
  • FIIs −0.40 pp
  • Public −0.31 pp

How it drifted, 12 quarters

Over this window the public fell from 41.8% to 33.2% — −8.6 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 40.9%, FIIs 4.6%, DIIs 12.7%, Public 41.8%.Dec '23: Promoters 40.9%, FIIs 4.0%, DIIs 13.9%, Public 41.2%.Mar '24: Promoters 40.9%, FIIs 4.2%, DIIs 14.2%, Public 40.8%.Jun '24: Promoters 40.9%, FIIs 6.1%, DIIs 13.8%, Public 39.2%.Sep '24: Promoters 40.9%, FIIs 8.8%, DIIs 13.5%, Public 36.8%.Dec '24: Promoters 40.9%, FIIs 10.0%, DIIs 15.8%, Public 33.3%.Mar '25: Promoters 40.9%, FIIs 10.0%, DIIs 15.6%, Public 33.4%.Jun '25: Promoters 40.9%, FIIs 9.8%, DIIs 15.8%, Public 33.5%.Sep '25: Promoters 40.9%, FIIs 9.1%, DIIs 17.0%, Public 33.1%.Dec '25: Promoters 40.9%, FIIs 8.5%, DIIs 17.4%, Public 33.2%.Mar '26: Promoters 40.9%, FIIs 8.5%, DIIs 17.0%, Public 33.6%.Jun '26: Promoters 40.9%, FIIs 9.4%, DIIs 16.5%, Public 33.2%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 3 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Jupiter Life Line Hospitals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ajay Pratap Thakker 20.74%unchanged
Western Medical Solutions Llp 8.70%unchanged
SBI Healthcare Opportunities Fund Mutual fund7.77%unchanged
Ankit Ajay Thakker 6.67%unchanged
JM Financial Products Limited NBFC / DFI3.42%unchanged
Goldman Sachs Funds - Goldman Sachs India Equity P Global fund house2.75%unchanged
Mihir Wire Industries Pvt Ltd 2.15%unchanged
Neeta Devang Gandhi 2.10%unchanged
Kirtika Ajay Thakker 2.03%unchanged
SBI Life Insurance Co. Ltd Insurer2.01%−0.44 pp
Dr Navin Ramji Davda 2.00%unchanged
JM Financial And Investment Consultancy Services 1.91%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in JLHL

Filings to Aug 2026

2 new, 3 added, 0 trimmed, 0 sold out — net +79.02 L shares (+31.7%).

Held by funds
₹999 Cr
6 schemes
Biggest holder
SBI MultiCap Fund
₹591 Cr · 2.4% of that fund
SchemeHoldingLast month
SBI MultiCap Fund SBI Mutual Fund₹591 Crheld
SBI Healthcare Opportunities Fund SBI Mutual Fund₹148 Cr+3.11 L
HDFC Multi Cap Fund HDFC Mutual Fund₹98 Cr+27.58 L
HDFC Pharma and Healthcare Fund HDFC Mutual Fund₹72 Cr+21.25 L
HDFC Small Cap Fund HDFC Mutual Fund₹57 Crnew
HDFC Flexi Cap Fund HDFC Mutual Fund₹33 Crnew

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

3 added, 0 trimmed — net +79.02 L shares (+31.7%)

Funds are sitting on
+220%
vs est. average cost
Held by funds
₹999 Cr
6 schemes · ≈ 56% of the company
Biggest holder
SBI MultiCap Fund
₹591 Cr · 2.4% of that fund
Longest holder
SBI Healthcare Opportunities Fund
3y 1m · since Aug '23

Shares held by these funds +4288%

Aug '23 3.25 cr shares Jul '26

What the price assumes

Growth the price implies
33.6% a year
for 7 years, fading to 4%
It has actually compounded at
Not enough history
The gap
—
between what it did and what it must do
Price today ₹279.15

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Jupiter Life Line Hospitals Limited

Guides on how to read this kind of business and the numbers that matter.